These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 7821334)
1. Short review on monoamine oxidase and its inhibitors. Kanazawa I Eur Neurol; 1994; 34 Suppl 3():36-9. PubMed ID: 7821334 [TBL] [Abstract][Full Text] [Related]
2. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Youdim MB; Riederer PF Neurology; 2004 Oct; 63(7 Suppl 2):S32-5. PubMed ID: 15477584 [No Abstract] [Full Text] [Related]
3. Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. LeWitt PA; Segel SA; Mistura KL; Schork MA Clin Neuropharmacol; 1993 Aug; 16(4):332-7. PubMed ID: 8374913 [TBL] [Abstract][Full Text] [Related]
4. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119 [No Abstract] [Full Text] [Related]
5. MAO-B inhibitor know-how: back to the pharm. Lewitt PA Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057 [No Abstract] [Full Text] [Related]
6. Rasagiline in Parkinson's disease: the show must go on. Jost WH Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684 [No Abstract] [Full Text] [Related]
7. Safinamide (Xadago) for Parkinson's disease. Med Lett Drugs Ther; 2017 Sep; 59(1529):151-153. PubMed ID: 28880847 [No Abstract] [Full Text] [Related]
8. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors. Henchcliffe C; Schumacher HC; Burgut FT Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338 [TBL] [Abstract][Full Text] [Related]
10. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Youdim MB; Riederer P Mov Disord; 1993; 8 Suppl 1():S8-13. PubMed ID: 8302308 [TBL] [Abstract][Full Text] [Related]
11. Clinical trials of neuroprotection for Parkinson's disease. LeWitt PA Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583 [No Abstract] [Full Text] [Related]
17. Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson's Disease. Robakis D; Fahn S CNS Drugs; 2015 Jun; 29(6):433-41. PubMed ID: 26164425 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
19. Preclinical versus clinical neuroprotection. Grünblatt E; Schlösser R; Gerlach M; Riederer P Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689 [No Abstract] [Full Text] [Related]
20. Drugs for Parkinson's disease. Treat Guidel Med Lett; 2011 Jan; 9(101):1-6; quiz 2 p following 6. PubMed ID: 21304446 [No Abstract] [Full Text] [Related] [Next] [New Search]